Allergy Therapeutics plc announced unaudited consolidated earnings results for the six months ended December 31, 2012. For the period, the company's revenue was GBP 25,749,000 against GBP 28,526,000 a year ago. Operating profit was GBP 5,277,000 against GBP 8,005,000 a year ago. Profit before tax was GBP 5,138,000 against GBP 8,190,000 a year ago. Profit for the period was GBP 4,949,000 against GBP 8,562,000 a year ago. Diluted earnings per share was 1.17 pence against 2.66 pence a year ago. Net cash generated by operating activities was GBP 4,100,000 against GBP 7,566,000 a year ago. Payments for intangible assets was GBP 12,000 against GBP 663,000 a year ago. Payments for property plant and equipment was GBP 227,000 against GBP 218,000 a year ago.

Allergy Therapeutics plc announced that they will report first half, 2013 results on Mar 25, 2013

Paladin Labs Inc. announced that it has entered into an exclusive Canadian distribution agreement with Allergy Therapeutics plc for Pollinex(R)-R (modified ragweed tyrosine adsorbate), an allergy vaccine for the treatment of allergic rhinitis due to ragweed pollen. In addition, Paladin also received an option to acquire distribution rights to Pollinex(R)-R in Sub-Saharan Africa. Under the agreement Paladin will co-promote the product with Takeda Canada Inc. for the first eight months before taking over all selling and distribution activities. Financial terms of the agreement were not disclosed. Pollinex(R)-R is a short-course immunotherapy vaccine of modified ragweed tyrosine adsorbate used to reduce the severity of allergic symptoms caused by exposure to ragweed. Pollinex(R)-R is administered weekly in four separate doses over the course of about one month prior to the start of the ragweed season.